⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27408768 | 0.97 | — | — | |
| SCHEMBL4553323 | 0.69 | — | — | |
| SCHEMBL13740193 | 0.67 | — | — | |
| SCHEMBL14249193 | 0.67 | — | — | |
| SCHEMBL219146 | 0.62 | — | — | |
| SCHEMBL8973287 | 0.61 | — | — | |
| SCHEMBL29615421 | 0.59 | — | — | |
| SCHEMBL5376674 | 0.59 | — | — | |
| SCHEMBL26292 | 0.58 | — | — | |
| SCHEMBL1827788 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116675675-A | Preparation method of lenacipam intermediate compound serving as AIDS treatment drug | 北京康立生医药技术开发有限公司 | 2023-09-01 | — | — | CN | claimed |
| EP-4017853-A1 | HETEROCYCLIC PYRAZOLE DERIVATIVES AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | Development Center for Biotechnology (TW) | 2022-06-29 | — | — | EP | claimed |
| EP-0278603-B1 | CONDENSED PYRAZOLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FARMITALIA CARLO ERBA S.r.l. (IT) | 1992-12-02 | — | — | EP | claimed |
| WO-1986007357-A3 | CYCLOPENTAPYRAZOLE AND TETRAHYDROINDAZOLE COMPOUNDS | THE UPJOHN COMPANY (US) | 1987-04-23 | — | — | WO | claimed |
| CN-116854630-B | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections | 吉利德科学公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12590125-B2 | Peptide inhibitors for the inhibition of HIV capsid | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2026-03-31 | — | — | US | disclosed |
| WO-2025226510-A1 | LPAR1 INHIBITORS | ABBVIE INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| CN-120078775-A | Capsid inhibitors for the treatment of HIV | 吉利德科学公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-120053446-A | Capsid inhibitors for the treatment of HIV | 吉利德科学公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-120053445-A | Capsid inhibitors for the treatment of HIV | 吉利德科学公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-120053447-A | Capsid inhibitors for the treatment of HIV | 吉利德科学公司 | 2025-05-30 | — | — | CN | disclosed |
| EP-0370955-A1 | Herbicidally active N-phenyl azoles | CIBA-GEIGY AG (CH) | 1990-05-30 | — | — | EP | disclosed |
| US-4851425-A | Cyclopentapyrazole and tetrahydroindazole compounds and their use as anti-inflammatory and anti-allergic agents | THE UPJOHN COMPANY (US) | 1989-07-25 | — | — | US | disclosed |
| US-4851425-A | Cyclopentapyrazole and tetrahydroindazole compounds and their use as anti-inflammatory and anti-allergic agents | THE UPJOHN COMPANY (US) | 1989-07-25 | — | — | US | disclosed |
| US-4851425-A | Cyclopentapyrazole and tetrahydroindazole compounds and their use as anti-inflammatory and anti-allergic agents | THE UPJOHN COMPANY (US) | 1989-07-25 | — | — | US | disclosed |
| EP-0226624-A1 | CYCLOPENTAPYRAZOLE AND TETRAHYDROINDAZOLE COMPOUNDS | THE UPJOHN COMPANY (US) | 1987-07-01 | — | — | EP | disclosed |
| WO-1986007357-A3 | CYCLOPENTAPYRAZOLE AND TETRAHYDROINDAZOLE COMPOUNDS | THE UPJOHN COMPANY (US) | 1987-04-23 | — | — | WO | disclosed |
| WO-1986007357-A3 | CYCLOPENTAPYRAZOLE AND TETRAHYDROINDAZOLE COMPOUNDS | THE UPJOHN COMPANY (US) | 1987-04-23 | — | — | WO | disclosed |
| WO-1986007357-A2 | CYCLOPENTAPYRAZOLE AND TETRAHYDROINDAZOLE COMPOUNDS | UPJOHN CO (US) | 1986-12-18 | — | — | WO | disclosed |